Literature DB >> 35975259

ADVANCES IN RADIOTHERAPY OF ADRENAL GLAND LESIONS.

X E Bacinschi1, R M Anghel2.   

Abstract

Primary adrenal tumors include a broad variety of lesions, from nonfunctioning incidentalomas to secreting adrenocortical adenomas including Aldosteronism, Cushing or androgen secreting lesions. Primary tumors can occur either in the cortex or the medulla of the adrenal glands, having different histopathological features and also different clinical appearances and treatment approaches. In addition, the adrenal glands can become distant metastatic sites of numerous primary malignancies. The first line of treatment in a broad variety of cases is surgery. After pathology results, in selected cases, apart the oncologic approach, radiotherapy could be an important therapeutic tool. In this paper we will discuss the role of radiotherapy in the treatment of adrenal gland lesions. ©2021 Acta Endocrinologica (Buc).

Entities:  

Keywords:  SBRT; adrenal lesions; adrenalectomy; local response; radiotherapy

Year:  2022        PMID: 35975259      PMCID: PMC9365415          DOI: 10.4183/aeb.2022.134

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   1.104


  26 in total

Review 1.  Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases.

Authors:  Gargi Kothari; Alexander V Louie; David Pryor; Ian Vela; Simon S Lo; Bin S Teh; Shankar Siva
Journal:  Chin Clin Oncol       Date:  2017-09

Review 2.  Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.

Authors:  Jenny Welander; Peter Söderkvist; Oliver Gimm
Journal:  Endocr Relat Cancer       Date:  2011-12-01       Impact factor: 5.678

Review 3.  Genetics of adrenocortical tumours.

Authors:  T Åkerström; T Carling; F Beuschlein; P Hellman
Journal:  J Intern Med       Date:  2016-12       Impact factor: 8.989

Review 4.  [Hypofractionated stereotactic body radiation therapy for adrenal metastases].

Authors:  G Dupic; J Biau; A Bellière-Calandry; M Lapeyre
Journal:  Cancer Radiother       Date:  2017-07-03       Impact factor: 1.018

Review 5.  Adrenal Tumors in Adults.

Authors:  Andre Pinto; Justine A Barletta
Journal:  Surg Pathol Clin       Date:  2015-12

6.  Impact of postoperative radiotherapy on the outcomes of resected adrenocortical carcinoma-a real-world, population-based study.

Authors:  Omar Abdel-Rahman
Journal:  Strahlenther Onkol       Date:  2021-09-02       Impact factor: 3.621

7.  Short-term effectiveness and safety of CT-guided radioactive iodine-125 seed implantation for treatment of adrenal metastases.

Authors:  Yingwen Hou; Ruibao Liu; Yali Cui; Yan Liu; Houbin Sun; Yi Yang; Linan Yin
Journal:  J Contemp Brachytherapy       Date:  2022-04-01

8.  Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.

Authors:  Alice Boilève; Elise Mathy; Charles Roux; Matthieu Faron; Julien Hadoux; Lambros Tselikas; Abir Al Ghuzlan; Ségolène Hescot; Sophie Leboulleux; Thierry de Baere; Livia Lamartina; Frédéric Deschamps; Eric Baudin
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 5.958

Review 9.  Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery.

Authors:  Matthias Guckenberger; Wolfgang W Baus; Oliver Blanck; Stephanie E Combs; Jürgen Debus; Rita Engenhart-Cabillic; Tobias Gauer; Anca L Grosu; Daniela Schmitt; Stephanie Tanadini-Lang; Christos Moustakis
Journal:  Strahlenther Onkol       Date:  2020-05       Impact factor: 3.621

Review 10.  Technological quality requirements for stereotactic radiotherapy : Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy.

Authors:  Daniela Schmitt; Oliver Blanck; Tobias Gauer; Michael K Fix; Thomas B Brunner; Jens Fleckenstein; Britta Loutfi-Krauss; Peter Manser; Rene Werner; Maria-Lisa Wilhelm; Wolfgang W Baus; Christos Moustakis
Journal:  Strahlenther Onkol       Date:  2020-03-24       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.